Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?
Paul Sargos, John P. Christodouleas(Elekta (Sweden)), S. Larré(Centre Hospitalier Universitaire d'Angers), Amit Bahl(At Bristol), Brian C. Baumann(Lawrence Livermore National Laboratory), Jason A. Efstathiou(Massachusetts General Hospital), Vedang Murthy(Homi Bhabha National Institute), Guilhem Roubaud(Institut Bergonié), Shahrokh F. Shariat(Universitätszahnklinik Wien), Libni Eapen(University of Ottawa), Pierre Richaud(Institut Bergonié), M. Orré(Institut Bergonié)
Cited by 19
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
|World Journal of Urology|2016|471